Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An update from MaxCyte ( (MXCT) ) is now available.
MaxCyte, Inc. has announced the issuance of 19,904 shares of common stock in response to the exercise of share options and vesting of restricted stock units, bringing the total issued stock capital to 105,711,093 shares. This update allows shareholders to calculate their interest changes in the company’s stock capital, reflecting the company’s ongoing developments in the cell engineering sector.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell-engineering industry, focused on providing platform technologies that advance the discovery, development, and commercialization of next-generation cell therapeutics. Their ExPERT™ platform, based on Flow Electroporation® technology, supports the cell therapy market from discovery to commercialization. MaxCyte offers four instruments, a range of proprietary processing assemblies, and software protocols, all backed by a global intellectual property portfolio.
Average Trading Volume: 44,266
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £350.5M
For an in-depth examination of MXCT stock, go to TipRanks’ Stock Analysis page.
